Genitourinary Cancers

Two new studies presented at the Annual Scientific Meeting of the American Urological Association offer an improved understanding of some genetic underpinnings of prostate cancer.

An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.

The FDA has granted accelerated approval to avelumab (Bavencio) for treating locally advanced or metastatic urothelial carcinoma patients whose disease progressed following treatment with platinum-containing chemotherapy.

The FDA has approved durvalumab (Imfinzi) for the treatment of patients with advanced urothelial carcinoma whose disease has progressed after treatment with platinum-containing chemotherapy.

The use of nephron-sparing surgery to treat stage I renal tumors increased between 2009 to 2013 in Australia, showing increased compliance with international guidelines.

A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab.

The FDA has expanded its approval of atezolizumab (Tecentriq) for the treatment of advanced bladder cancer to include the initial therapy of patients who are not eligible for cisplatin chemotherapy.

From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study.

Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.

The use of multi-parametric magnetic resonance imaging could help avoid a repeat prostate biopsy in some men, according to a new study.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

The PD-L1 antibody avelumab was well tolerated and had promising antitumor activity in patients with refractory metastatic urothelial carcinoma.

Maintenance vinflunine yielded longer progression-free survival vs best supportive care in advanced urothelial carcinoma patients after disease control with chemotherapy.

BMI was inversely correlated with serum adiponectin levels in RCC, and low BMI and high adiponectin might be associated with disease aggressiveness and survival in patients with the disease.

The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial.

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.

Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.

Sorafenib, gemcitabine, and cisplatin had promising activity and was well tolerated in patients with muscle-invasive urothelial bladder cancer.

A mathematical approach revealed a set of criteria that could help define prostate cancer patients with poor prognosis, according to a new analysis. This could help many patients avoid overtreatment.

Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.

Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.

Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.

Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.

Dacomitinib induction therapy has shown activity in HPV-negative, locally advanced or metastatic penile squamous cell carcinoma.

Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma.

Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.